Terminal glycosylation and disease: Influence on cancer and cystic fibrosis

Thomas F. Scanlin, Mary Catherine Glick

Research output: Contribution to journalReview articlepeer-review

39 Scopus citations

Abstract

Terminal glycosylation has been a recurring theme of the laboratory. In cystic fibrosis (CF), decreased sialic acid and increased fucosyl residues in α1,3 position to antennary N-acetyl glucosamine is the CF glycosylation phenotype. The glycosylation phenotype is reversed by transfection of CF airway cells with wtCFTR. In neuronal cells, polymers of α2,8sialyl residues are prominent in oligodendrocytes and human neuroblastoma. These findings are discussed in relationship to early studies in our laboratories and those of other investigators. The potential extension of these concepts to future clinical therapeutics is presented.

Original languageEnglish (US)
Pages (from-to)617-626
Number of pages10
JournalGlycoconjugate Journal
Volume17
Issue number7-9
DOIs
StatePublished - 2000
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Keywords

  • Cystic fibrosis
  • Lactosylated polylysine gene therapy vector
  • Polyα2,8sialic acid
  • Sialic acid
  • Surface membrane glycoforms
  • α1,3fucose
  • α1,6fucose

Fingerprint Dive into the research topics of 'Terminal glycosylation and disease: Influence on cancer and cystic fibrosis'. Together they form a unique fingerprint.

Cite this